Christina Duesing, MD

Klinik f�r Rheumatologie
D�sseldorf, Germany

Presentation(s):

• 1198: Induction of stable, GC-free remission in patients with severe, therapy-refractory anti-synthetase syndrome after using the bispecific CD19xCD3 T cell engager blinatumomab

  Monday, October 27, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure information not submitted.